SHR-7787

SHR-7787 is an investigational bispecific T-cell engager (BiTE) being developed by Shanghai Hengrui Pharmaceutical for the treatment of advanced solid tumors. The drug is designed as a novel antineoplastic agent, with its primary mechanism of action involving the engagement and activation of T-cells to target and kill tumor cells. While the precise molecular targets have not been publicly disclosed, its classification as a BiTE suggests it binds both T-cells (typically via CD3) and a tumor-associated antigen on cancer cells, facilitating immune-mediated cytotoxicity. Clinical development is ongoing in China, with Phase I/II trials evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with unresectable or metastatic solid tumors[1][2][3][8].